Cite
Janku F, Angenendt P, Tsimberidou AM, et al. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015;6(27):24581doi: 10.18632/oncotarget.5663.
Janku, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., Piha-Paul, S. A., Zinner, R. G., Bedikian, A. Y., Overman, M. J., Kee, B. K., Kim, K. B., Kopetz, E. S., Luthra, R., Diehl, F., Meric-Bernstam, F., & Kurzrock, R. (2015). Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 6(27), 24581. https://doi.org/10.18632/oncotarget.5663
Janku, Filip, et al. "Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies." Oncotarget vol. 6,27 (2015): 24581. doi: https://doi.org/10.18632/oncotarget.5663
Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15;6(27):24581. doi: 10.18632/oncotarget.5663. PMID: 26405159; PMCID: PMC4695208.
Copy
Download .nbib
